From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT
Before treatment | After 3M treatment | After 6M treatment | |
---|---|---|---|
All patients | All patients | All patients | |
Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | |
DAS28 | 4.7±1.4 (2.5-8.9) | 3.2±1.5 (1.3-6.3)* | 3.1±1.6 (0.9-6.7)* |
DAS28-CRP | 3.2±1.4 (1.3-8.9) | 2.4±1.3 (1.0-5.2)* | 2.4±1.4 (1.0-5.2)* |
SDAI | 20.2±16.6 (3.2-75.1) | 10.4±10.8 (0.7-40.9)* | 11.7±13.3 (0.1-42.8)* |
CDAI | 18.1±15.4 (2.8-68) | 9.8±10.0 (0.7-39)* | 11.1±13.0 (0.1-42.8)* |
ESR (mm/h) | 67.8±33.9 (14–122) | 23.4±26.0 (3–107)* | 20.9±25.0 (2–98)* |
CRP (mg/dl) | 2.16±2.72 (0.11-7.10) | 0.60±1.48 (0.01-5.73)* | 0.53±1.55 (0.00-6.25)* |
MMP-3 (ng/ml) | 302.6±254.2 (28.4-792.6) | 150.1±153.4 (32.1-600.7)* | 139.6±152.3 (10.0-545.4)* |
Tender joints count | 3.6±5.9 (0–24) | 2.5±3.6 (0–13) | 2.9±5.0 (0–18) |
Swollen joints count | 5.7±5.8 (0–24) | 3.1±3.6 (0–15)* | 3.8±4.9 (0–15) |
P-VAS | 39.9±29.0 (0–100) | 22.5±24.1 (0–70)* | 23.0±24.1 (0–71)* |
E-VAS | 47.9±26.9 (0–100) | 19.4±15.9 (0–55)* | 20.5±21.8 (1–77)* |